Panama maintains a two-tier healthcare system with quality concentrated in Panama City and limited infrastructure in rural provinces. The country eliminated malaria from Panama City and the Canal Zone by 1956 but endemic transmission persists in Darién Province, Guna Yala, parts of Bocas del Toro, and forested areas of Veraguas. Between 2015 and 2020, Panama reported approximately 1,200 to 1,800 malaria cases annually, with Plasmodium vivax accounting for roughly 95 percent of infections and Plasmodium falciparum comprising the remainder. The Pan American Health Organization confirmed chloroquine-resistant falciparum malaria in Darién Province in the 1980s, a status that persists. Travelers visiting any forested or rural area below 2,000 meters elevation outside the Panama City metropolitan area and the central Canal corridor face transmission risk during rainy months from May through December, when Anopheles mosquito populations peak. Prophylaxis decisions require consultation with a physician familiar with current resistance patterns, but atovaquone-proguanil and doxycycline remain standard recommendations for areas with documented falciparum resistance. The Barú Volcano summit at 3,475 meters elevation and Panama City proper are above transmission thresholds, but neighboring provinces including Chiriquí lowlands and Bocas del Toro coastal areas maintain year-round risk.
Dengue fever occurs throughout Panama with cyclical outbreaks every three to five years. The Ministry of Health reported 3,087 confirmed dengue cases in 2019 before a surge to 16,746 cases in 2020, with serotypes DENV-1 and DENV-2 predominating. Panama City, Colón, David, and Chitré account for most cases due to urban Aedes aegypti populations breeding in stagnant water containers. Severe dengue, formerly called dengue hemorrhagic fever, causes approximately 1 to 5 percent of hospitalized cases depending on outbreak year. Chikungunya entered Panama in 2014 with the Caribbean epidemic, producing 3,200 reported cases that year before becoming endemic at lower levels. Zika virus arrived in 2015, peaking at 4,400 reported cases in 2016 before declining to sporadic transmission. Both viruses share the same Aedes vector as dengue, making prevention measures identical. No vaccine exists for chikungunya or Zika. Dengue vaccination with TAK-003, approved in some countries, requires evidence of prior infection before administration, limiting utility for most travelers. Vector protection through DEET-containing repellents at concentrations of 20 to 30 percent, permethrin-treated clothing, and screened or air-conditioned accommodations constitutes the only reliable prevention for all three arboviruses.
Yellow fever vaccination requirements depend on arrival patterns. Panama does not require yellow fever vaccination for travelers arriving from the United States, Canada, or Europe. Travelers arriving from countries with risk of yellow fever transmission must present proof of vaccination if aged nine months or older. The list of such countries includes most of sub-Saharan Africa and tropical South America. Panama itself contains minimal yellow fever risk, with the last confirmed case reported in 1974 in Darién Province near the Colombian border. The World Health Organization classifies Darién Province and Guna Yala comarca as areas where yellow fever transmission is possible but unconfirmed since 1974. Some travelers receive vaccination before visiting these areas despite absence of recent cases because Aedes and Haemagogus mosquito vectors exist and the vaccine provides protection lasting decades. Countries with strict entry requirements sometimes demand yellow fever proof from travelers who visited Panama, depending on their interpretation of WHO risk maps. Verification of specific destination country requirements becomes necessary before travel. Yellow fever vaccine administration requires International Certificate of Vaccination documentation, valid ten days after injection for first-time recipients and immediately for booster doses.
Routine immunizations require verification against standard schedules. Measles immunity verification holds particular importance following Panama's 2019 outbreak that produced 213 confirmed cases, breaking a 19-year absence of endemic transmission. The outbreak originated in Guna Yala comarca and spread to Panama City before containment through emergency vaccination. Adults born after 1970 without documented measles vaccination or laboratory confirmation of immunity should receive MMR vaccine. Tetanus-diphtheria boosters at ten-year intervals follow standard recommendations. Pertussis vaccination coverage gaps in Panamanian adults create ongoing transmission, making Tdap preferred over Td for adults who have not received pertussis vaccine since childhood.
Hepatitis A vaccine deserves consideration for any traveler eating outside international hotel restaurants. Panama's water treatment covers major cities but food handling practices create risk. The Ministry of Health reported hepatitis A incidence of 2.8 cases per 100,000 population in 2018, with higher rates in Bocas del Toro and Guna Yala. Two-dose vaccination provides immunity lasting 25 years or longer. Travelers who cannot complete the two-dose series before departure should receive the first dose, which produces protective antibodies in 95 percent of recipients within two weeks. Hepatitis B vaccination follows standard risk-based recommendations. Healthcare workers, travelers anticipating medical care, and persons with potential sexual contacts face elevated risk. The three-dose series requires six months to complete but accelerated four-dose schedules compress this to three months.
Typhoid fever occurs in Panama at rates lower than most Central American countries but cases cluster in rural provinces. Oral typhoid vaccine requires four capsules taken on alternate days, with the full series completed one week before travel. Injectable polysaccharide vaccine requires one dose given at least two weeks before departure. Neither vaccine provides complete protection, making food and water precautions necessary regardless of immunization status. Booster doses for oral vaccine are needed every five years and for injectable vaccine every two years during continued risk.
Rabies vaccine consideration depends on activity profile. Panama reports 5 to 15 human rabies cases annually, primarily from bat exposures but occasionally from infected dogs in rural areas. The Ministry of Health documented vampire bat rabies in cattle-raising areas of Darién, Veraguas, and Chiriquí provinces. Travelers spending time in caves, working with animals, or traveling to areas more than two hours from rabies immunoglobulin sources should consider pre-exposure vaccination. The three-dose pre-exposure series simplifies post-exposure treatment by eliminating the need for rabies immunoglobulin, which faces supply limitations in Panama outside major hospitals. Post-exposure treatment without pre-exposure vaccination requires both vaccine and immunoglobulin, with the immunoglobulin component often unavailable in rural clinics. Any bat contact, even without obvious bite, requires immediate medical evaluation regardless of vaccination status.
Altitude considerations apply only to Barú Volcano. The summit at 3,475 meters produces acute mountain sickness in non-acclimatized persons, particularly those ascending rapidly from sea level. Symptoms begin 6 to 12 hours after arrival and include headache, nausea, fatigue, and sleep disturbance. Acetazolamide 125 milligrams twice daily starting the day before ascent reduces incidence and severity. Gradual ascent with overnight stays at intermediate elevations near 2,000 meters prevents symptoms more reliably than medication. High-altitude pulmonary edema and high-altitude cerebral edema occur rarely below 4,000 meters but documented cases exist at Barú's elevation. Immediate descent constitutes the only reliable treatment for either condition.